Zymergen combined AI, automation, and biology to engineer microbes for specialty materials. After a high-profile IPO in 2021 at $3B+ valuation, the company abandoned its lead product and was acquired by Ginkgo Bioworks in 2022 for approximately $300M — a cautionary tale about scale-up risk in synthetic biology.